1. Williams, M.; Coyle, J. T; Shaikh, S.; Decker, M. W Annu. Rep. Med. Chem. 2001, 35, 1-10.
2. Uhl, G. R.; Grow, R. W Arch. Gen. Psychiatr. 2004, 61, 223-229.
3. First, M. B.; Tasman, A. DSM-IV-TR Diagnosis, Etiology and Treatment; Wiley: New York, 2004.
5. Kupfer, D. J.; First, M. B.; Regier, D. A. A Research Agenda for DSM-V; American Psychiatric Publishing: Washington, DC, 2002.
6. Sunderland, T; Linker, G.; Mirza, M.; Putnam, K. T; Friedman, D. L.; Kimmel, L. H.; Bergeson, J.; Manetti, C. J.; Zimmermann, M.; Tang, B. JAMA 2003, 289, 2094-2103.
7. Coyle, J. T.; Tsai, G. Int. Rev. Neurobiol. 2004, 59, 491-515.
8. Lieberman, J. A.; Stroup, T. S. S.; McEvoy, J. P et al. N. Engl. J. Med. 2004, 353, 1209-1223.
9. Weiner, D. M.; Meltzer, H. Y; Veinbergs, I.; Donohue, E. M.; Spalding, T A.; Smith, T T; Mohell, N.; Harvey, S. C.; Lameh, J. H.; Nash, N. et al. Psychopharmacol. 2004, 177, 207-216.
10. Caspi, A.; Sugden, K.; Moffitt, T. E.; Taylor, A.; Craig, I. W; Harrington, H.; McClay, J.; Mill, J.; Martin, J.; Braithwaite, A.; Poulton, R. Science 2003, 301, 386-389.
11. Sneader, W Drug Discovery: The Evolution of Modern Medicines; John Wiley: Chichester, UK, 1985.
12. Korpi, E. R.; Sinkkonen, S. T Pharmacol. Ther. 2006, 109, 12-32.
13. NIDA Research Report - HIV/AIDS NIH Publication No. 06-5760, November, 2005.
15. Roman, G. C.; Tatemichi, T K.; Erkinjuntti, T. et al. Neurology 1993, 43, 250-260.
16. Waldmeier, P; Bozyczko-Coyne, D. B.; Williams, M.; Vaught, J. Biochem. Pharmacol. 2006, 72, 1197-1206.
17. Williams, M. Biochem. Pharmacol. 2005, 70, 1707-1716.
18. Roth, B. L.; Sheffler, D. J.; Kroeze, W K. Nat. Rev Drug Disc. 2004, 3, 353-359.
19. Horrabin, D. F Nat. Rev. Drug Disc. 2003, 2, 151-154.
20. Spedding, M.; Jay, T; Costa e Silva, J.; Perret, L. Nat. Rev. Drug Disc. 2005, 4, 467-478.
21. FitzGerald, G. A. Nat. Rev. Drug Disc. 2005, 4, 815-818.
22. Surtees, P. G.; Wainwright, N. W J.; Willis-Owen, S. A. G.; Luben, R.; Day, N. E.; Flint, J. Biol. Psychiatr. 2006, 59, 224-229.
Michael J Marino received his PhD in 1995 from the University of Pittsburgh Department of Neuroscience where he employed behavioral and electrophysiological methods to the study of G-proteins and G protein-coupled receptors. As a postdoctoral fellow with Dr Jeff Conn at Emory University, he performed pioneering work on the role of metabotropic glutamate receptors in regulating the circuitry of the basal ganglia. This work led to the identification of potential targets for the treatment of Parkinson's disease. In 2001, he joined Merck Research Laboratories where he worked on novel drug discovery projects related on the modulatory control of brain circuitry underlying Parkinson's disease and related movement disorders. He is currently Associate Director of CNS biology at Cephalon, where he continues to focus on drug discovery for disorders of the CNS.
Michael Williams received his PhD (1974) from the Institute of Psychiatry and his Doctor of Science degree in pharmacology (1987) both from the University of London. Dr Williams has worked in the US-based pharmaceutical industry for 30 years at Merck, Sharp and Dohme Research Laboratories, Nova Pharmaceutical, CIBA-Geigy, and Abbott Laboratories. He retired from the latter in 2000 and served as a consultant with various biotechnology/ pharmaceutical venture capital companies in the USA and Europe. In 2003 he joined Cephalon, Inc. in West Chester, where he is Vice President of Worldwide Discovery Research. He has published some 300 articles, book chapters, and reviews and is an Adjunct Professor in the Department of Molecular Pharmacology and Biological Chemistry at the Feinberg School of Medicine, Northwestern University, Chicago, IL.
© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medicinal Chemistry II
No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 6) 0-08-044519-5; pp. 1-16
Was this article helpful?